Total Payments
$931,810
2024 Payments
$98,881
Companies
60
Transactions
2,296
Medicare Patients
2,243
Medicare Billing
$1.7M
Payment Breakdown by Category
Other$710,619 (76.3%)
Travel$113,645 (12.2%)
Consulting$60,860 (6.5%)
Food & Beverage$44,883 (4.8%)
Research$1,126 (0.1%)
Education$676.80 (0.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $701,669 | 410 | 75.3% |
| Travel and Lodging | $113,645 | 235 | 12.2% |
| Consulting Fee | $60,860 | 13 | 6.5% |
| Food and Beverage | $44,883 | 1,595 | 4.8% |
| Compensation for serving as faculty or as a speaker for a medical education program | $6,500 | 3 | 0.7% |
| Honoraria | $2,450 | 1 | 0.3% |
| Unspecified | $1,126 | 6 | 0.1% |
| Education | $676.80 | 33 | 0.1% |
Payments by Type
General
$930,684
2,290 transactions
Research
$1,126
6 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Lilly USA, LLC | $263,349 | 473 | $0 (2024) |
| Novo Nordisk Inc | $237,690 | 454 | $0 (2024) |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $118,354 | 151 | $0 (2024) |
| ABBVIE INC. | $63,195 | 231 | $0 (2024) |
| Kaneka Pharma America LLC | $55,537 | 3 | $0 (2021) |
| Amgen Inc. | $49,527 | 151 | $0 (2024) |
| Janssen Pharmaceuticals, Inc | $34,461 | 94 | $0 (2024) |
| Regeneron Healthcare Solutions, Inc. | $26,316 | 88 | $0 (2024) |
| Esperion Therapeutics, Inc. | $21,952 | 35 | $0 (2022) |
| Abbott Laboratories | $15,097 | 21 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $98,881 | 259 | Lilly USA, LLC ($67,162) |
| 2023 | $93,638 | 258 | Lilly USA, LLC ($54,314) |
| 2022 | $137,902 | 325 | Lilly USA, LLC ($57,847) |
| 2021 | $138,105 | 281 | Novo Nordisk Inc ($43,361) |
| 2020 | $96,581 | 213 | Lilly USA, LLC ($33,533) |
| 2019 | $161,137 | 354 | Novo Nordisk Inc ($40,261) |
| 2018 | $88,532 | 290 | Novo Nordisk Inc ($28,791) |
| 2017 | $117,033 | 316 | Boehringer Ingelheim Pharmaceuticals, Inc. ($31,679) |
All Payment Transactions
2,296 individual payment records from CMS Open Payments — Page 1 of 92
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/30/2024 | Xeris Pharmaceuticals, Inc. | RECORLEV (Drug) | Food and Beverage | In-kind items and services | $15.06 | General |
| Category: Adrenal steroidogenesis inhibitor | ||||||
| 12/23/2024 | Amgen Inc. | TEPEZZA (Biological) | Food and Beverage | In-kind items and services | $26.66 | General |
| Category: Inflammation/Rare Disease | ||||||
| 12/18/2024 | Bayer Healthcare Pharmaceuticals Inc. | Kerendia (Drug) | Food and Beverage | In-kind items and services | $23.60 | General |
| Category: Cardio-renal | ||||||
| 12/16/2024 | Lilly USA, LLC | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $23.76 | General |
| Category: Diabetes | ||||||
| 12/16/2024 | Amgen Inc. | EVENITY (Biological), Prolia | Food and Beverage | In-kind items and services | $18.29 | General |
| Category: Bone Health | ||||||
| 12/13/2024 | Lilly USA, LLC | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $23.22 | General |
| Category: Diabetes | ||||||
| 12/13/2024 | ABBVIE INC. | SYNTHROID (Drug) | Food and Beverage | In-kind items and services | $15.35 | General |
| Category: IMMUNOLOGY | ||||||
| 12/11/2024 | Novo Nordisk Inc | Wegovy (Drug) | Food and Beverage | In-kind items and services | $18.24 | General |
| Category: Obesity | ||||||
| 12/10/2024 | Regeneron Healthcare Solutions, Inc. | EVKEEZA (Biological) | Food and Beverage | In-kind items and services | $21.61 | General |
| Category: CARDIOVASCULAR AND METABOLISM | ||||||
| 12/09/2024 | Regeneron Pharmaceuticals, Inc. | EVKEEZA (Biological) | Food and Beverage | In-kind items and services | $21.00 | General |
| Category: CARDIOVASCULAR AND METABOLISM | ||||||
| 12/06/2024 | Madrigal Pharmaceuticals | REZDIFFRA (Drug) | Honoraria | Cash or cash equivalent | $2,450.00 | General |
| Category: LIVER DISEASE | ||||||
| 12/04/2024 | Ascendis Pharma Inc | — | Food and Beverage | In-kind items and services | $21.47 | General |
| 12/03/2024 | Novo Nordisk Inc | Ozempic (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $750.00 | General |
| Category: Diabetes | ||||||
| 12/02/2024 | Chiesi USA, Inc. | JUXTAPID (Drug) | Food and Beverage | Cash or cash equivalent | $17.92 | General |
| Category: HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA | ||||||
| 11/26/2024 | ABBVIE INC. | SYNTHROID (Drug) | Food and Beverage | In-kind items and services | $15.57 | General |
| Category: IMMUNOLOGY | ||||||
| 11/26/2024 | ABBVIE INC. | SYNTHROID (Drug) | Food and Beverage | In-kind items and services | $0.74 | General |
| Category: IMMUNOLOGY | ||||||
| 11/21/2024 | Lilly USA, LLC | JARDIANCE (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,050.00 | General |
| Category: Diabetes | ||||||
| 11/19/2024 | Bayer Healthcare Pharmaceuticals Inc. | Kerendia (Drug) | Food and Beverage | In-kind items and services | $24.90 | General |
| Category: Cardio-renal | ||||||
| 11/18/2024 | Amgen Inc. | Repatha (Biological) | Food and Beverage | In-kind items and services | $23.01 | General |
| Category: Cardiology | ||||||
| 11/16/2024 | Novo Nordisk Inc | Ozempic (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,156.25 | General |
| Category: Diabetes | ||||||
| 11/16/2024 | Novo Nordisk Inc | Ozempic (Drug) | Travel and Lodging | In-kind items and services | $754.25 | General |
| Category: Diabetes | ||||||
| 11/16/2024 | Novo Nordisk Inc | Ozempic (Drug) | Food and Beverage | In-kind items and services | $40.74 | General |
| Category: Diabetes | ||||||
| 11/14/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,050.00 | General |
| Category: DIABETES | ||||||
| 11/13/2024 | Novo Nordisk Inc | — | Food and Beverage | In-kind items and services | $22.74 | General |
| 11/12/2024 | Regeneron Healthcare Solutions, Inc. | EVKEEZA (Biological) | Food and Beverage | In-kind items and services | $16.14 | General |
| Category: CARDIOVASCULAR AND METABOLISM | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ALIROCUMAB IN PATIENTS WITH HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA UNDERGOING LIPID APHERESIS THERAPY | Regeneron Pharmaceuticals, Inc. | $1,126 | 6 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 7 | 409 | 807 | $1.3M | $399,984 |
| 2022 | 8 | 504 | 965 | $1.4M | $460,869 |
| 2021 | 11 | 600 | 948 | $1.1M | $375,925 |
| 2020 | 10 | 730 | 1,205 | $1.3M | $415,896 |
Total Patients
2,243
Total Services
3,925
Medicare Billing
$1.7M
Procedure Codes
36
All Medicare Procedures & Services
36 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 36516 | Mechanical separation of plasma and abnormal antibodies from blood | Office | 2023 | 15 | 261 | $1.2M | $364,103 | 31.0% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 135 | 184 | $46,368 | $16,575 | 35.7% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 94 | 101 | $35,552 | $13,302 | 37.4% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 47 | 53 | $9,434 | $2,570 | 27.2% |
| 83036 | Hemoglobin a1c level | Office | 2023 | 84 | 146 | $3,066 | $1,381 | 45.1% |
| 95251 | Continuous monitoring of blood sugar level in tissue fluid using sensor under skin with interpretation and report | Office | 2023 | 22 | 50 | $4,000 | $1,342 | 33.6% |
| 99443 | Telephone medical discussion with physician, 21-30 minutes | Office | 2023 | 12 | 12 | $1,740 | $710.84 | 40.9% |
| 36516 | Mechanical separation of plasma and abnormal antibodies from blood | Office | 2022 | 15 | 293 | $1.3M | $414,262 | 31.4% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 155 | 219 | $55,188 | $20,480 | 37.1% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 108 | 112 | $39,424 | $14,469 | 36.7% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 58 | 63 | $11,214 | $3,244 | 28.9% |
| 99443 | Telephone medical discussion with physician, 21-30 minutes | Office | 2022 | 27 | 33 | $4,785 | $3,047 | 63.7% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2022 | 14 | 14 | $6,034 | $2,299 | 38.1% |
| 83036 | Hemoglobin a1c level | Office | 2022 | 98 | 181 | $3,801 | $1,727 | 45.4% |
| 95251 | Continuous monitoring of blood sugar level in tissue fluid using sensor under skin with interpretation and report | Office | 2022 | 29 | 50 | $4,000 | $1,341 | 33.5% |
| 36516 | Mechanical separation of plasma and abnormal antibodies from blood | Office | 2021 | 13 | 223 | $1.0M | $323,134 | 32.2% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 176 | 234 | $51,900 | $21,435 | 41.3% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 109 | 110 | $33,065 | $13,845 | 41.9% |
| 99443 | Physician telephone patient service, 21-30 minutes of medical discussion | Office | 2021 | 65 | 78 | $11,310 | $5,505 | 48.7% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 53 | 61 | $9,674 | $3,627 | 37.5% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Office | 2021 | 16 | 16 | $6,560 | $2,383 | 36.3% |
| 83036 | Hemoglobin a1c level | Office | 2021 | 94 | 139 | $2,919 | $1,294 | 44.3% |
| 95250 | Ambulatory continuous glucose (sugar) monitoring for a minimum of 72 hours | Office | 2021 | 11 | 11 | $3,300 | $1,269 | 38.5% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Office | 2021 | 12 | 12 | $3,888 | $1,219 | 31.3% |
| 95251 | Ambulatory continuous glucose (sugar) including interpretation and report for a minimum of 72 hours | Office | 2021 | 30 | 42 | $3,360 | $1,139 | 33.9% |
About Dr. Stephan Babirak, MD
Dr. Stephan Babirak, MD is a Internal Medicine healthcare provider based in Scarborough, Maine. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/19/2006. The National Provider Identifier (NPI) number assigned to this provider is 1689619884.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Stephan Babirak, MD has received a total of $931,810 in payments from pharmaceutical and medical device companies, with $98,881 received in 2024. These payments were reported across 2,296 transactions from 60 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($701,669).
As a Medicare-enrolled provider, Babirak has provided services to 2,243 Medicare beneficiaries, totaling 3,925 services with total Medicare billing of $1.7M. Data is available for 4 years (2020–2023), covering 36 distinct procedure/service records.
Ad
Practice Information
- Specialty Internal Medicine
- Other Specialties Diabetes & Metabolism
- Location Scarborough, ME
- Active Since 06/19/2006
- Last Updated 03/26/2013
- Taxonomy Code 207R00000X
- Entity Type Individual
- NPI Number 1689619884
Products in Payments
- JARDIANCE (Drug) $229,239
- MOUNJARO (Drug) $129,853
- Ozempic (Drug) $94,599
- LIPOSORBER (Device) $55,417
- Repatha (Biological) $48,618
- RYBELSUS (Drug) $42,677
- Rybelsus (Drug) $40,348
- INVOKANA (Drug) $34,324
- Synthroid (Drug) $30,748
- NEXLIZET (Drug) $21,633
- PRALUENT (Biological) $19,338
- SYNTHROID (Drug) $15,781
- Tresiba (Drug) $13,833
- Androgel (Drug) $13,609
- PRALUENT (Drug) $12,839
- Victoza (Drug) $11,910
- PRALUENT ALIROCUMAB INJECTION (Biological) $10,023
- Xultophy 100/3.6 (Drug) $9,028
- EVKEEZA (Biological) $7,532
- FREESTYLE LIBRE 3 (Device) $6,308
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Internal Medicine Doctors in Scarborough
Alan Hanley, Md, MD
Internal Medicine — Payments: $32,395
Internal Medicine $32,395
Erik Andrews, Md, MD
Internal Medicine — Payments: $16,745
Internal Medicine $16,745
Dr. Shiva Annamalai, Md, MD
Internal Medicine — Payments: $8,313
Internal Medicine $8,313
Dr. Jaidip Chakravartti, M.d, M.D
Internal Medicine — Payments: $5,561
Internal Medicine $5,561
Anuj Mediratta, M.d, M.D
Internal Medicine — Payments: $3,236
Internal Medicine $3,236
Dr. Esther Shao, M.d, M.D
Internal Medicine — Payments: $1,745
Internal Medicine $1,745